Measured in a cell proliferation assay using NIH-3T3 mouse fibroblast cells, the EC50 for this effect is less than 0.5ng/ml.
Product Details
Product Details
Product Specification
| Species | Rat |
| Accession | Q06175 |
| Amino Acid Sequence | Asp63-Leu148 |
| Expression System | E.coli |
| Molecular Weight | 10 kDa (Reducing) |
| Purity | >95% by SDS-PAGE. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Diabetes. 2020 Mar;69(3):369-380. |
Background
Heparin-Binding Epidermal Growth Factor-like Growth Factor (HB-EGF) is a multifunctional growth factor that plays a crucial role in various cellular processes, including proliferation, differentiation, and tissue repair. In rats, HB-EGF has been extensively studied for its role in pancreatic beta-cell proliferation and glucose homeostasis.
HB-EGF has been studied extensively in rat models of diabetes to understand its role in beta-cell regeneration and proliferation. For instance, HB-EGF has been shown to promote beta-cell proliferation in rats with partial pancreatectomy. This suggests that HB-EGF could be a potential therapeutic target for enhancing beta-cell mass and improving glucose homeostasis in diabetes.
Picture
Picture
Bioactivity
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
